Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 26, 2026, 4:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

mTBI Identification and Monitoring Through Retinal Scanning

NCT06142435
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
Head and Intraocular Trauma Tool
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Single Ascending Dose Study in Participants With LCA10

NCT03872479
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital
Interventions
EDIT-101
Drug
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 4:41 AM EDT
Active, not recruiting No phase listed Observational

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

NCT05605782
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 26, 2026, 4:41 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Recruiting Not applicable Interventional

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

NCT05438732
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
smaller incision, new generation implantable miniature telescope (SING-IMT)
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

NCT01678963
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Squalamine lactate, Vehicle control
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Bakersfield, California • Beverly Hilss, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 26, 2026, 4:41 AM EDT
Terminated No phase listed Observational

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

NCT00078091
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Not applicable Interventional

Exercise and RP (AVAMC and Emory)

NCT03381235
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Spin exercise
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

The FIGHT-RP1 Study

NCT03063021
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Not applicable Interventional

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

NCT00002247
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:41 AM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT

NCT03688243
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 26, 2026, 4:41 AM EDT
Recruiting No phase listed Observational

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

NCT05589714
View directory record Official record
Conditions
Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Results available

Efalizumab to Treat Uveitis

NCT00280826
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Efalizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 26, 2026, 4:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939
View directory record Official record
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Interventions
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
Drug
Lead sponsor
Ocugen
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

NCT07588100
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
RO7663498
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Glendale, California • Oak Forest, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

NCT04919499
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 765128, Sham comparator
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
EYE001 anti-VEGF aptamer
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:41 AM EDT
Active, not recruiting No phase listed Observational

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

NCT05573984
View directory record Official record
Conditions
Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
Interventions
Not listed
Lead sponsor
PYC Therapeutics
Industry
Eligibility
10 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial

NCT04259047
View directory record Official record
Conditions
Mild Cognitive Impairment, Diabetes
Interventions
Diabetes Regulation for Eyesight and Memory, Enhanced Usual Care
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 26, 2026, 4:41 AM EDT
Completed No phase listed Observational

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

NCT03314207
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 26, 2026, 4:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration

NCT00277784
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 26, 2026, 4:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

NCT00996437
View directory record Official record
Conditions
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab, Saline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 26, 2026, 4:41 AM EDT